BRF110是一种口服活跃的Nurr1-RXRα-选择性雷克斯类物质,增强BDNF表达,而不会增加甘油三
Xenophon Asvos1, Mohamed A El Mubarak2, Theodoros Karampelas3
1Department of Materials Science and Engineering, University of Ioannina, Ioannina 45110, Greece.
Journal of medicinal chemistry
|February 13, 2025
概括
研究人员开发了BRF110,一种新的穿透大脑的rexinoid. 这种化合物选择性地向Nurr1-RXRα异构体,提供神经保护并减轻与其他rexinoids见过的副作用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 视网膜X受体α (RXRα) 激动剂正在用于神经退行性疾病.
- 由于缺乏选择性和副作用,现有的RXRα激动剂如贝克沙罗具有局限性.
- 针对特定的RXRα异构体提供了改善治疗结果的潜在策略.
研究的目的:
- 发现和描述一种具有对Nurr1-RXRα异构体增强选择性的新型rexinoid.
- 与以前的化合物相比,改善体内稳定性和大脑透率.
- 在临床前模型中评估新型化合物的治疗潜力和安全性.
主要方法:
- 结构-活性关系 (SAR) 研究和替代金胺的生物活性评估.
- 在体外测试以确认异构体选择性.
- 在小鼠体内研究以评估大脑透,对MPP+的神经保护和BDNF转录.
- 生物化学分析以评估甘油三水平.
主要成果:
- 发现了BRF110,一种穿透大脑的Nurr1-RXRα异构体选择性rexinoid.
- BRF110在多巴胺细胞中表现出针对MPP+诱导的毒性的神经保护作用.
- 在小鼠中,BRF110增加了BDNF转录.
- 与贝克萨罗不同的是,BRF110没有提高甘油三水平.
结论:
- BRF110代表了帕金森病和潜在的其他神经退行性疾病的有希望的治疗候选者.
- 异构体选择性rexinoids提供了一种改善RXR向药物的治疗指数的策略.
- 向调节RXRα异构体可以减轻非向副作用,克服rexinoid药物开发中的关键挑战.
相关概念视频
01:31Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
01:26Adrenergic Receptors: β Subtype
1.5K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.5K
01:24Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291